TRF-1101 Assessment in Sickle Cell Disease

• Status: Terminated
• Trial end date: 2009-05-01

Summary

This study is designed to assess the safety, tolerability, and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain associated with sickle cell disease.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: TRF Pharma, Inc